Bio-Rad Laboratories, Inc.
BIO
Positions held
Your positionsBIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Bio-Rad Laboratories operates in a competitive medical devices industry, which is expected to grow significantly due to increasing healthcare demands and technological advancements.
- In Q2 2026, Bio-Rad reported a revenue increase of 10% compared to the previous quarter, reaching $651 million.
- The company's gross margin improved to 53.1% in Q2 2026, up from 52.3% in Q1 2026.
- The healthcare sector faces regulatory challenges that can impact the profitability and operational efficiency of companies like Bio-Rad.
- Bio-Rad's net income was negative at -$527.1 million in Q1 2026, indicating potential financial instability.
- The company has a trailing P/E ratio of 46.75, suggesting that it may be overvalued compared to its earnings growth.
Fundamentals
| Market cap | $9.64B | Enterprise value | $9.39B | Trailing P/E | 45.68 | Forward P/E | 36.34 |
| PEG | 4.01 | Price / book | 1.34 | Beta | 1.07 | Dividend yield | 0.00% |
| Revenue growth | -0.1% | Earnings growth | 18.7% | Gross margin | 52.0% | Operating margin | 11.2% |
| Profit margin | 8.6% | ROE | 3.1% | ROA | 1.7% | Debt / equity | 0.19 |
| Current ratio | 3.14 | Free cash flow | $283.19M | Analyst recommendation | hold | Mean target | $328.33 |
| 52w high | $396.23 | 52w low | $236.73 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $651M | $592M | $693M | $653M | $652M |
| Op margin | 11.2% | 5.8% | 7.8% | 9.8% | 11.8% |
| Net income | $371M | -$527M | $720M | -$342M | $318M |
| Gross margin | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% |
| Gross profit | $346M | $309M | $345M | $343M | $345M |
| Operating income | $72.6M | $34.1M | $53.9M | $63.9M | $77.1M |
- Revenue +10% vs prior quarter ($651M vs $592M).
- Gross margin 53.1% (was 52.3% prior quarter).
- Operating margin expanded to 11.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.7B | $2.8B | — |
| Op margin | 8.5% | 10.5% | 12.6% | 17.0% | — |
| Net income | $760M | -$1.8B | -$637M | -$3.6B | — |
| Gross margin | 51.9% | 53.7% | 53.4% | 55.9% | — |
| Gross profit | $1.3B | $1.4B | $1.4B | $1.6B | — |
| Operating income | $219M | $269M | $338M | $475M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates
2026-10-01 · Why Bio Rad Laboratories (BIO) Is Back In The Spotlight
2026-09-28 · Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
2026-09-26 · Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
2026-09-24 · Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
2026-09-24 · Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
2026-09-23 · Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
Price (daily)
Full chart · RSI · MACD · patterns